谷歌浏览器插件
订阅小程序
在清言上使用
VIPCreated with Sketch.

KRASG12C/TP53 Co-Mutations Identify Long-Term Responders to First Line Palliative Treatment with Pembrolizumab Monotherapy in PD-L1 High (≥50%) Lung Adenocarcinoma

Nikolaj Frost,Jens Kollmeier,Claudia Vollbrecht,Christian Grah,Burkhard Matthes,Dennis Pultermann,Maximilian von Laffert,Heike Lueders,Elisabeth Olive,Matthias Raspe,Thomas Mairinger,Sebastian Ochsenreither,Torsten Blum,Michael Hummel,Norbert Suttorp,Martin Witzenrath,Christian Grohe

Translational Lung Cancer Research（2021）

引用 22|浏览15
暂无评分
关键词
Non-small cell lung cancer (NSCLC),checkpoint inhibitors,KRAS mutations,TP53 mutations
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要